Risk factors
Immix Biopharma (IMMX) risk factors
Item 1A of every Immix Biopharma, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors56 risks5 new1 dropped4 reworded
Cash and cash equivalents grew to $100.4 million as of December 31, 2025, up from $17.7 million.
Filed Mar 25, 2026 - FY2024 10-K risk factors52 risks
Immix Biopharma faces substantial capital requirements, relying heavily on existing cash of $17.7 million and external grants. The company carries zero product revenues and depends entirely on unproven clinical candidates. Intellectual property defense and regulatory compliance dictate operational viability.
Filed Mar 25, 2025